HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,662,681 | +3.5% | 148,238 | -2.3% | 0.35% | +7.7% |
| Q2 2023 | $5,473,476 | -1.6% | 151,746 | -47.9% | 0.33% | -8.2% |
| Q1 2023 | $5,562,966 | +77747.3% | 291,040 | +131.8% | 0.36% | -29.0% |
| Q4 2022 | $7,146 | -99.9% | 125,582 | -0.0% | 0.50% | +37.7% |
| Q3 2022 | $4,967,000 | -42.2% | 125,619 | -35.7% | 0.36% | -33.4% |
| Q2 2022 | $8,597,000 | -13.2% | 195,391 | -21.4% | 0.54% | +5.2% |
| Q1 2022 | $9,909,000 | +4.3% | 248,461 | +5.1% | 0.52% | +12.9% |
| Q4 2021 | $9,502,000 | -9.8% | 236,301 | -8.7% | 0.46% | -12.9% |
| Q3 2021 | $10,534,000 | -7.2% | 258,947 | +3.6% | 0.53% | -7.4% |
| Q2 2021 | $11,351,000 | +10.4% | 249,970 | +1.4% | 0.57% | +6.0% |
| Q1 2021 | $10,280,000 | -1.9% | 246,575 | +0.4% | 0.54% | +3.3% |
| Q4 2020 | $10,484,000 | -22.9% | 245,476 | -52.6% | 0.52% | -24.7% |
| Q3 2020 | $13,601,000 | -3.6% | 517,526 | -1.7% | 0.69% | -8.2% |
| Q2 2020 | $14,112,000 | – | 526,389 | – | 0.75% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,305,403 | $233,209,000 | 10.86% |
| BB BIOTECH AG | 7,379,832 | $89,148,000 | 3.13% |
| SENZAR ASSET MANAGEMENT, LLC | 550,544 | $6,650,572,000 | 1.72% |
| SNYDER CAPITAL MANAGEMENT L P | 2,232,114 | $26,964,000 | 1.69% |
| Sterling Global Strategies LLC | 22,000 | $266,000 | 0.98% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,290,024 | $112,223,000 | 0.98% |
| MSD Partners, L.P. | 965,000 | $11,657,000 | 0.94% |
| DOHENY ASSET MANAGEMENT /CA | 130,950 | $1,582,000 | 0.81% |
| Taylor Wealth Management Partners | 128,110 | $1,548,000 | 0.69% |
| Bellevue Group AG | 318,000 | $3,841,000 | 0.69% |